TIZVENI Concentrate for solution for infusion Ref.[110144] Active ingredients: Tislelizumab

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: Beigene Ireland Limited, 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland, Tel. +353 1 566 7660, E-mail: bg.ireland@beigene.com

Product name and form

Tizveni 100 mg concentrate for solution for infusion.

Pharmaceutical Form

Concentrate for solution for infusion (sterile concentrate).

Clear to slightly opalescent, colourless to slightly yellowish solution.

The solution has a pH of approximately 6.5 and an osmolality of approximately 270 to 330 mOsm/kg.

Qualitative and quantitative composition

Each ml of concentrate for solution for infusion contains 10 mg tislelizumab.

Each vial of 10 ml contains 100 mg tislelizumab.

Tislelizumab is an Fc-engineered humanised immunoglobulin G4 (IgG4) variant monoclonal antibody produced in recombinant Chinese hamster ovary cells.

Excipient with known effect: Each ml of concentrate for solution for infusion contains 0.069 mmol (or 1.6 mg) sodium.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Tislelizumab

Tislelizumab is a humanised immunoglobulin G4 (IgG4) variant monoclonal antibody against PD-1, binding to the extracellular domain of human PD-1. It competitively blocks the binding of both PD-L1 and PD-L2, inhibiting PD-1-mediated negative signalling and enhancing the functional activity in T cells in in vitro cell-based assays.

List of Excipients

Sodium citrate dihydrate
Citric acid monohydrate
L-histidine hydrochloride monohydrate
L-histidine
Trehalose dihydrate
Polysorbate 20
Water for injections

Pack sizes and marketing

10 ml of Tizveni concentrate is provided in a clear Type 1 glass vial, with a grey chlorobutyl stopper with FluroTec coating and seal cap with a flip-off button.

Tizveni is available in unit packs containing 1 vial and in multipacks containing 2 (2 packs of 1) vials.

Marketing authorization holder

Beigene Ireland Limited, 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland, Tel. +353 1 566 7660, E-mail: bg.ireland@beigene.com

Marketing authorization dates and numbers

EU/1/24/1797/001-002

Drugs

Drug Countries
TIZVENI Lithuania

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.